SLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2

Nature Communications

Volumn 5, Issue , 2014, Pages

  Naudin, Cécile ^a   Sirvent, Audrey ^a   Leroy, Cédric ^a   Larive, Romain ^a   Simon, Valérie ^a   Pannequin, Julie ^b   Bourgaux, Jean François ^c   Pierre, Josiane ^d   Robert, Bruno ^e   Hollande, Frédéric ^b,f   Roche, Serge ^a  

^a Centre National de la Recherche Scientifique   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSERM   (France)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; MESSENGER RNA; PROTEIN KINASE B; PROTEIN SH2; PROTEIN SH3; SLAP PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBE4A PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE P60; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SLA PROTEIN, HUMAN; UBE4A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ABUNDANCE; CANCER; HUMAN GEOGRAPHY; PUBLIC HEALTH; SIGNALING; SUBSTRATE; TUMOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CARCINOGENICITY; CELL MIGRATION; CELL TRANSFORMATION; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEEDBACK SYSTEM; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTESTINE EPITHELIUM; LIVER METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; UBIQUITINATION; WNT SIGNALING PATHWAY; COLORECTAL TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPHA2; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84893083218     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4159     Document Type: Article

References (45)

1. Lieberman, D. Screening for colorectal cancer in average-risk populations. Am. J. Med. 119, 728-735 (2006)
2. Comella, P., Casaretti, R., Avallone, A. & Franco, L. Optimizing the management of metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. 75, 15-26 (2009)
3. Hollande, F., Pannequin, J. & Joubert, D. The long road to colorectal cancer therapy: searching for the right signals. Drug Resist. Updat. 13, 44-56 (2009)
4. Yeatman, T. J. A renaissance for SRC. Nat. Rev. Cancer 4, 470-480 (2004)
5. Summy, J. M. & Gallick, G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22, 337-358 (2003)
6. Sirvent, A., Benistant, C. & Roche, S. oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am. J. Cancer Res. 2, 357-371 (2012)
7. Oneyama, C. et al. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol. Cell 30, 426-436 (2008)
8. Sirvent, A. et al. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 29, 1303-1315 (2010)
9. Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94-101 (2005)
10. Luo, W. et al. Global impact of oncogenic Src on a phosphotyrosine proteome. J. Proteome Res. 7, 3447-3460 (2008)
11. Leroy, C. et al. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res. 69, 2279-2286 (2009)
12. Sirvent, A., Vigy, O., Orsetti, B., Urbach, S. & Roche, S. analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts. Mol. Cell Proteomics 11, 1937-1950 (2012)
13. Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer. 10, 165-180 (2010)
14. Beauchamp, A. & Debinski, W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin. Cell Dev. Biol. 23, 109-115 (2011)
15. Dragone, L. L., Shaw, L. A., Myers, M. D. & Weiss, A. SLAP, a regulator of immunoreceptor ubiquitination, signaling, and trafficking. Immunol. Rev. 232, 218-228 (2009)
16. Roche, S. et al. Src-like adaptor protein (Slap) is a negative regulator of mitogenesis. Curr. Biol. 8, 975-978 (1998)
17. Sirvent, A., Leroy, C., Boureux, A., Simon, V. & Roche, S. The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner. Oncogene 27, 3494-3500 (2008)
18. Myers, M. D., Dragone, L. L. & Weiss, A. Src-like adaptor protein downregulates T cell receptor (TCR)-CD3 expression by targeting TCRzeta for degradation. J. Cell Biol. 170, 285-294 (2005)
19. Sosinowski, T., Pandey, A., Dixit, V. M. & Weiss, A. Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling. J. Exp. Med. 191, 463-474 (2000)
20. Myers, M. D. et al. Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat. Immunol. 7, 57-66 (2006)
21. Pandey, A., Duan, H. & Dixit, V. M. Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J. Biol. Chem. 270, 19201-19204 (1995)
22. Sosinowski, T., Killeen, N. & Weiss, A. The Src-like adaptor protein downregulates the T cell receptor on CD4?CD8? thymocytes and regulates positive selection. Immunity 15, 457-466 (2001)
23. Dragone, L. L. et al. Src-like adaptor protein (SLAP) regulates B cell receptor levels in a c-Cbl-dependent manner. Proc. Natl Acad. Sci. USA 103, 18202-18207 (2006)
24. Liontos, L. M. et al. The Src-like adaptor protein regulates GM-CSFR signaling and monocytic dendritic cell maturation. J. Immunol. 186, 1923-1933 (2011)
25. Lebigot, I. et al. Up-regulation of SLAP in FLI-1-transformed erythroblasts interferes with EpoR signaling. Blood 102, 4555-4562 (2003)
26. Colnot, S. et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab. Invest. 84, 1619-1630 (2004)
27. Chen, X., Tan, P. H., Zhang, Y. & Pei, D. On-bead screening of combinatorial libraries: reduction of nonspecific binding by decreasing surface ligand density. J. Comb. Chem. 11, 604-611 (2009)
28. Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K. I. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111-33120 (2001)
29. Tang, J., Sawasdikosol, S., Chang, J. H. & Burakoff, S. J. SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling. Proc. Natl Acad. Sci. USA 96, 9775-9780 (1999)
30. Walker-Daniels, J., Riese, 2nd D. J. & Kinch, M. S. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. 1, 79-87 (2002)
31. Muzny, D. M. et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012)
32. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012)
33. Caren, H., Holmstrand, A., Sjoberg, R. M. & Martinsson, T. The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours. Eur. J. Cancer 42, 381-387 (2006)
34. Sakiyama, T., Fujita, H. & Tsubouchi, H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn?s disease. Inflamm. Bowel Dis. 14, 310-317 (2008)
35. Herath, N. I. & Boyd, A. W. The role of Eph receptors and ephrin ligands in colorectal cancer. Int. J. Cancer 126, 2003-2011 (2009)
36. Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligandindependent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009)
37. Larsen, A. B. et al. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 5, 283-293 (2007)
38. Brantley-Sieders, D. M. et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 118, 64-78 (2008)
39. Taddei, M. L. et al. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am. J. Pathol. 174, 1492-1503 (2009)
40. Fang, W. B., Brantley-Sieders, D. M., Hwang, Y., Ham, A. J. & Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 283, 16017-16026 (2008)
41. Sharma, M. R. et al. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest. New Drugs 30, 1211-1215 (2012)
42. Manes, G., Bello, P. & Roche, S. Slap negatively regulates Src mitogenic function but does not revert Src-induced cell morphology changes. Mol. Cell Biol. 20, 3396-3406 (2000)
43. Pannequin, J. et al. Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors. Gastroenterology 133, 1554-1568 (2007)
44. Roche, S. et al. Requirement of phospholipase C gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Rasindependent pathways. EMBO J. 15, 4940-4948 (1996)
45. Rhinn, H. et al. How to make siRNA lipoplexes efficient? Add a DNA cargo. Biochim. Biophys. Acta 1790, 219-230 (2009)